Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of fgf receptor signaling

Cancer Cell

Volumn 23, Issue 4, 2013, Pages 489-501

  Herbert, Corentin ^a   Schieborr, Ulrich ^b   Saxena, Krishna ^b   Juraszek, Jarek ^c   De Smet, Frederik ^d,e   Alcouffe, Chantal ^a   Bianciotto, Marc ^a   Saladino, Giorgio ^c   Sibrac, David ^a   Kudlinzki, Denis ^b   Sreeramulu, Sridhar ^b   Brown, Alan ^f   Rigon, Patrice ^a   Herault, Jean Pascal ^a   Lassalle, Gilbert ^a   Blundell, Tom L ^f   Rousseau, Frederic ^e   Gils, Ann ^e   Schymkowitz, Joost ^e   Tompa, Peter ^g,h   Herbert, Jean Marc ^a   Carmeliet, Peter ^d,e   Gervasio, Francesco Luigi ^c   Schwalbe, Harald ^b   Bono, Françoise ^a   more..

^a SANOFI   (France)

^b GOETHE UNIVERSITY   (Germany)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^h INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; SSR 128129E; UNCLASSIFIED DRUG;

ALLOSTERISM; ANGIOGENESIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG BINDING; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; INTERNALIZATION; MOLECULAR DYNAMICS; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 84876401041     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.02.018     Document Type: Article

References (33)

1. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
2. Belleudi F., Leone L., Nobili V., Raffa S., Francescangeli F., Maggio M., Morrone S., Marchese C., Torrisi M.R. Keratinocyte growth factor receptor ligands target the receptor to different intracellular pathways. Traffic 2007, 8:1854-1872.
3. Best R.B., Hummer G. Optimized molecular dynamics force fields applied to the helix-coil transition of polypeptides. J. Phys. Chem. B 2009, 113:9004-9015.
4. Bono F., De Smet F., Herbert C., DeBock K., Georgiadou M., Fons P., Tjwa M., Alcouffe C., Ny A., Bianciotto M., et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell 2013, 23:477-488. this issue.
5. Bretonnet A.S., Jochum A., Walker O., Krimm I., Goekjian P., Marcillat O., Lancelin J.M. NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding site. J. Med. Chem. 2007, 50:1865-1875.
6. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 2002, 1:198-210.
7. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8:41-54.
8. Coskun U., Grzybek M., Drechsel D., Simons K. Regulation of human EGF receptor by lipids. Proc. Natl. Acad. Sci. USA 2011, 108:9044-9048.
9. Duchardt E., Sigalov A.B., Aivazian D., Stern L.J., Schwalbe H. Structure induction of the T-cell receptor zeta-chain upon lipid binding investigated by NMR spectroscopy. ChemBioChem 2007, 8:820-827.
10. Dunker A.K., Oldfield C.J., Meng J., Romero P., Yang J.Y., Chen J.W., Vacic V., Obradovic Z., Uversky V.N. The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 2008, 9(Suppl 2):S1.
11. Gasparini G., Longo R., Toi M., Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2:562-577.
12. Hanoulle X., Melchior A., Sibille N., Parent B., Denys A., Wieruszeski J.M., Horvath D., Allain F., Lippens G., Landrieu I. Structural and functional characterization of the interaction between cyclophilin B and a heparin-derived oligosaccharide. J. Biol. Chem. 2007, 282:34148-34158.
13. Hilser V.J., Thompson E.B. Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc. Natl. Acad. Sci. USA 2007, 104:8311-8315.
14. Huppa J.B., Axmann M., Mörtelmaier M.A., Lillemeier B.F., Newell E.W., Brameshuber M., Klein L.O., Schütz G.J., Davis M.M. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature 2010, 463:963-967.
15. Irschick R., Trost T., Karp G., Hausott B., Auer M., Claus P., Klimaschewski L. Sorting of the FGF receptor 1 in a human glioma cell line. Histochem. Cell Biol. 2013, 139:135-148.
16. Laio A., Gervasio F.L. Metadynamics: a method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science. Rep. Prog. Phys. 2008, 71:126601.
17. Lovera S., Sutto L., Boubeva R., Scapozza L., Dölker N., Gervasio F.L. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 2012, 134:2496-2499.
18. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Cryst. 2007, 40:658-674.
19. Metallo S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 2010, 14:481-488.
20. Murshudov G.N., Dodson E.J., Vagin A.A. Application of maximum likelihood methods for macromolecular refinement. CCP4 Study Weekend Proceedings: Macromolecular Refinement 1996, 93-104. Daresbury Laboratory, Warrington, United Kingdom.
21. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
22. Park S.J., Borin B.N., Martinez-Yamout M.A., Dyson H.J. The client protein p53 adopts a molten globule-like state in the presence of Hsp90. Nat. Struct. Mol. Biol. 2011, 18:537-541.
23. Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407:1029-1034.
24. Piana S., Laio A. A bias-exchange approach to protein folding. J. Phys. Chem. B 2007, 111:4553-4559.
25. Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999, 98:641-650.
26. Reilly J.F., Mizukoshi E., Maher P.A. Ligand dependent and independent internalization and nuclear translocation of fibroblast growth factor (FGF) receptor 1. DNA Cell Biol. 2004, 23:538-548.
27. Saladino G., Gauthier L., Bianciotto M., Gervasio F.L. Assessing the performance of metadynamics and path variables in predicting the binding free energies of p38 inhibitors. J. Chem. Theory Comput. 2012, 8:1165-1170.
28. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
29. Sigalov A., Aivazian D., Stern L. Homooligomerization of the cytoplasmic domain of the T cell receptor zeta chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry 2004, 43:2049-2061.
30. Tompa P. Unstructural biology coming of age. Curr. Opin. Struct. Biol. 2011, 21:419-425.
31. Tompa P., Fuxreiter M. Fuzzy complexes: polymorphism and structural disorder in protein-protein interactions. Trends Biochem. Sci. 2008, 33:2-8.
32. Tzeng S.R., Kalodimos C.G. Dynamic activation of an allosteric regulatory protein. Nature 2009, 462:368-372.
33. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9:28-39.